Switch theme
Sign up to access all valuation multiples
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of therapies for patients with diseases of the central and peripheral nervous system. Geographically the research and development activities are performed in Italy and the United States.
1999
22
LTM Revenue $40.8M
LTM EBITDA $16.4M
$180M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Newron Pharmaceuticals has a last 12-month revenue of $40.8M and a last 12-month EBITDA of $16.4M.
In the most recent fiscal year, Newron Pharmaceuticals achieved revenue of $10.2M and an EBITDA of -$13.4M.
Newron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Newron Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.9M | $10.2M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$15.1M | -$13.4M | XXX | XXX | XXX |
| EBITDA Margin | -219% | -131% | XXX | XXX | XXX |
| Net Profit | -$16.9M | -$19.8M | XXX | XXX | XXX |
| Net Margin | -245% | -193% | XXX | XXX | XXX |
| Net Debt | $19.8M | $35.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Newron Pharmaceuticals's stock price is CHF 6 (or $7).
Newron Pharmaceuticals has current market cap of CHF 125M (or $141M), and EV of CHF 159M (or $180M).
See Newron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $180M | $141M | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Newron Pharmaceuticals has market cap of $141M and EV of $180M.
Newron Pharmaceuticals's trades at 4.2x LTM EV/Revenue multiple, and 10.4x LTM EBITDA.
Analysts estimate Newron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Newron Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $180M | XXX | XXX | XXX |
| EV/Revenue | 17.5x | XXX | XXX | XXX |
| EV/EBITDA | -13.4x | XXX | XXX | XXX |
| P/E | -7.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -15.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNewron Pharmaceuticals's NTM/LTM revenue growth is -71%
Newron Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Newron Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Newron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Newron Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -131% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -202% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 145% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 228% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Newron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Newron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Newron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Newron Pharmaceuticals founded? | Newron Pharmaceuticals was founded in 1999. |
| Where is Newron Pharmaceuticals headquartered? | Newron Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Newron Pharmaceuticals have? | As of today, Newron Pharmaceuticals has 22 employees. |
| Is Newron Pharmaceuticals publicy listed? | Yes, Newron Pharmaceuticals is a public company listed on SWX. |
| What is the stock symbol of Newron Pharmaceuticals? | Newron Pharmaceuticals trades under NWRN ticker. |
| When did Newron Pharmaceuticals go public? | Newron Pharmaceuticals went public in 2006. |
| Who are competitors of Newron Pharmaceuticals? | Similar companies to Newron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Newron Pharmaceuticals? | Newron Pharmaceuticals's current market cap is $141M |
| What is the current revenue of Newron Pharmaceuticals? | Newron Pharmaceuticals's last 12-month revenue is $40.8M. |
| What is the current EBITDA of Newron Pharmaceuticals? | Newron Pharmaceuticals's last 12-month EBITDA is $16.4M. |
| What is the current EV/Revenue multiple of Newron Pharmaceuticals? | Current revenue multiple of Newron Pharmaceuticals is 4.2x. |
| What is the current EV/EBITDA multiple of Newron Pharmaceuticals? | Current EBITDA multiple of Newron Pharmaceuticals is 10.4x. |
| What is the current revenue growth of Newron Pharmaceuticals? | Newron Pharmaceuticals revenue growth between 2023 and 2024 was 49%. |
| Is Newron Pharmaceuticals profitable? | Yes, Newron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
